NASDAQ:EYPT Eyepoint Pharmaceuticals (EYPT) Stock Price, News & Analysis $3.64 -0.08 (-2.02%) Closing price 03:59 PM EasternExtended Trading$3.64 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Eyepoint Pharmaceuticals Stock (NASDAQ:EYPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get EYPT alerts:Sign Up Key Stats Today's Range$3.54▼$3.7350-Day Range$3.45▼$14.7552-Week Range$3.41▼$19.11Volume1.73 million shsAverage Volume2.09 million shsMarket Capitalization$314.24 millionP/E RatioN/ADividend YieldN/APrice Target$25.70Consensus RatingHold Company Overview EyePoint Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on developing and delivering treatments for serious eye diseases. The company’s proprietary technology is designed to provide sustained, localized release of pharmaceutical compounds within the eye, with the goal of reducing treatment frequency and improving outcomes for patients and physicians. EyePoint’s commercial products include YUTIQ, an injectable fluocinolone acetonide implant for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye, and DEXYCU, a sustained-release dexamethasone intraocular suspension used to treat inflammation following ophthalmic surgery. The products are marketed in the United States. The company’s pipeline includes investigational sustained-release therapies for retinal diseases. Its lead development program, EYP-1901, is an intravitreal formulation of vorolanib being evaluated for conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint was formerly known as pSivida Corp. and adopted the EyePoint Pharmaceuticals name in 2018. The company is headquartered in Watertown, Massachusetts.AI Generated. May Contain Errors. Read More Eyepoint Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreEYPT MarketRank™: Eyepoint Pharmaceuticals scored higher than 69% of companies evaluated by MarketBeat, and ranked 266th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingEyepoint Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialEyepoint Pharmaceuticals has a consensus price target of $25.70, representing about 597.4% upside from its current price of $3.69.Amount of Analyst CoverageEyepoint Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eyepoint Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eyepoint Pharmaceuticals are expected to grow in the coming year, from ($3.51) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyepoint Pharmaceuticals is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyepoint Pharmaceuticals is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyepoint Pharmaceuticals has a P/B Ratio of 1.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Eyepoint Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted22.14% of the float of Eyepoint Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 1.72, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eyepoint Pharmaceuticals has recently decreased by 1.72%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEyepoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyepoint Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.33 News SentimentEyepoint Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Eyepoint Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest16 people have searched for EYPT on MarketBeat in the last 30 days. This is an increase of 23% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Eyepoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eyepoint Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders5.13% of the stock of Eyepoint Pharmaceuticals is held by insiders.Percentage Held by Institutions99.41% of the stock of Eyepoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eyepoint Pharmaceuticals' insider trading history. Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EYPT Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTSeptember 22 at 7:21 PM | globenewswire.comEyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded to Strong Sell Rating by Wall Street ZenSeptember 19, 2026 | americanbankingnews.comThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.September 24 at 1:00 AM | Golden Portfolio (Ad)Contrasting Bristol Myers Squibb (NYSE:BMY) and Eyepoint Pharmaceuticals (NASDAQ:EYPT)September 18, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTSeptember 17, 2026 | prnewswire.comEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 16, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTSeptember 15, 2026 | globenewswire.comEyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comSee More Headlines EYPT Stock Analysis - Frequently Asked Questions How have EYPT shares performed this year? Eyepoint Pharmaceuticals' stock was trading at $18.27 at the beginning of the year. Since then, EYPT shares have decreased by 79.8% and is now trading at $3.6850. How were Eyepoint Pharmaceuticals' earnings last quarter? Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.01) by $0.08. The company earned $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. Eyepoint Pharmaceuticals had a negative trailing twelve-month return on equity of 135.81% and a negative net margin of 10,994.73%. When did Eyepoint Pharmaceuticals' stock split? Eyepoint Pharmaceuticals shares reverse split before market open on Wednesday, December 9th 2020.The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Eyepoint Pharmaceuticals' major shareholders? Eyepoint Pharmaceuticals' top institutional investors include Principia Wealth Advisory LLC (0.75%), Wellington Management Group LLP (0.27%), California State Teachers Retirement System (0.12%) and Squarepoint Ops LLC (0.11%). Insiders that own company stock include Jay S Duker, Ye Liu, David Scott Jones, Dario A Paggiarino, Wendy F Dicicco, Michael Craig Pine, David R Guyer and Ramiro Ribeiro. View institutional ownership trends. How do I buy shares of Eyepoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eyepoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eyepoint Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA), Advanced Micro Devices (AMD) and Broadcom (AVGO). Company Calendar Last Earnings8/05/2026Today9/24/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 EYPT's financial health is in the Red zone, according to TradeSmith. EYPT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:EYPT CIK1314102 Webwww.eyepoint.bio Phone(617) 926-5000Fax617-926-5050Employees214Year Founded1987Price Target and Rating Average Price Target for Eyepoint Pharmaceuticals$25.70 High Price Target$68.00 Low Price Target$4.00 Potential Upside/Downside+605.1%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$231.96 million Net Margins-10,994.73% Pretax Margin-10,989.85% Return on Equity-135.81% Return on Assets-108.35% Debt Debt-to-Equity RatioN/A Current Ratio4.50 Quick Ratio4.46 Sales & Book Value Annual Sales$2.79 million Price / Sales112.71 Cash FlowN/A Price / Cash FlowN/A Book Value$3.70 per share Price / Book0.99Miscellaneous Outstanding Shares86,212,000Free Float81,789,000Market Cap$314.24 million OptionableOptionable Beta1.63 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:EYPT) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EYPT Stock Alerts